NCT07036978
Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer
StatusRecruiting
PhaseNot specified
SponsorChang Gung Memorial Hospital
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 7 words
- Start date changed from estimate of May 1, 2026 to May 28, 2026
- Study description shortened, about 29 words
- Site details revised
- Notable Start date: Aug 1, 2025 to May 1, 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Treatment response classification based on metabolomic profiles
Timeframe: At baseline (prior to treatment initiation) and at first radiographic evaluation (8-12 weeks after treatment initiation).
Secondary (1)
Correlation between immune-microbiome landscape and treatment outcomes
Arms and interventions
Pancreatic Cancer
Surgically Unresectable Pancreatic Cancer
Other: Collecting biospecimens
Sites
1 site in 1 country
- Linkou Chang Gung Memorial HospitalTaoyuan, Taiwan